Muscular Dystrophy and cannabis in Rhode Island
The state does not list this condition by name, but its statute or regulator permits a certifying physician to add conditions case-by-case. Patients should expect to bring full diagnostic records to the certification visit.
- ✗ No
- LEGAL
- Up to 2.5 oz over any 1…
- POSSESSION
- $50/yr
- STATE FEE
- 14–45 d
- TIMELINE
Rhode Island statute and program
The Rhode Island Medical Marijuana Program (Edward O. Hawkins and Thomas C. Slater Medical Marijuana Act) is the operating authority for Rhode Island patient certification. The authoritative legal text is: Rhode Island General Laws Chapter 21-28.11: The Rhode Island Cannabis Act. The program portal is at Rhode Island Medical Marijuana Program (Edward O. Hawkins and Thomas C. Slater Medical Marijuana Act).
What the evidence says about cannabis and Muscular Dystrophy
Muscular dystrophy refers to a group of more than 30 inherited genetic disorders characterized by progressive muscle weakness and degeneration caused by mutations in genes encoding proteins that maintain muscle-fiber integrity. The major clinical subtypes include:
For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Muscular Dystrophy page.
How to qualify in Rhode Island
The Rhode Island Medical Marijuana Program (Edward O. Hawkins and Thomas C. Slater Medical Marijuana Act) requires the following registration steps for a Muscular Dystrophy patient (or any qualifying diagnosis):
- Get a written certification from a Rhode Island healthcare practitioner. Any Rhode Island-licensed physician, physician assistant, advanced practice nurse, or out-of-state physician with a Rhode Island Medical Marijuana Program registration may issue the written certification stating that the patient has a debilitating medical condition under R.I. Gen. Laws §21-28.6-3. The Edward O. Hawkins / Thomas C. Slater Act permits practitioner-added "other medical condition or its treatment" beyond the enumerated list.
- Submit your patient application to the Office of Cannabis Regulation. The patient mails the completed Patient Registration Application, the Written Certification, a Rhode Island driver license or state ID copy, a passport-style photograph, and the registration fee to the Office of Cannabis Regulation at the Department of Business Regulation (DBR). Online submission is available through the DBR portal.
- Pay the $50 state registration fee. The annual patient registration card fee is $50, reduced to $10 for patients on Medicaid or SSI. Caregivers are $50 per caregiver with a separate background check. Compassion-center registration (the alternative for patients who do not want to register with a caregiver) carries the same fee structure.
- Receive the card and purchase from a compassion center. Patient registration cards are issued within roughly 35 days of complete application receipt. With the card, patients may purchase up to 2.5 ounces every 15 days from any Rhode Island licensed compassion center. Rhode Island honors out-of-state medical cards from qualifying states for purchase at compassion centers under its reciprocity statute. Adult-use retail also operates statewide for adults 21+.
- State registration fee
- $50
- Physician visit (typical)
- $150–$250
- Certification to card
- 14–45 days
- Out-of-state patients
- Eligible
- Minors
- Eligible with caregiver
For full Rhode Island registration steps, fees, and reciprocity rules, see the Rhode Island cannabis-laws page.
ICD-10 code
A certifying physician documenting Muscular Dystrophy for the Rhode Island medical cannabis program will typically record ICD-10 G71.0 or SNOMED-CT 76670001 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.
Frequently asked questions
Does Rhode Island list Muscular Dystrophy as a qualifying condition for medical cannabis?
Not by name, but Rhode Island permits physician discretion. Under Rhode Island Medical Marijuana Program (Edward O. Hawkins and Thomas C. Slater Medical Marijuana Act), a certifying physician can add a condition like Muscular Dystrophy on a case-by-case basis when the physician judges that the patient would benefit from medical cannabis. This is different from a state where the qualifying-condition list is fixed in statute. Whether a particular physician will certify Muscular Dystrophy depends on the physician's training, the strength of the patient's documentation, and the practitioner's reading of the available evidence — evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). Patients should expect to bring full diagnostic records to the certification visit.
How do I get a Rhode Island medical marijuana card for Muscular Dystrophy?
Step one is finding a physician licensed in Rhode Island who is registered with Rhode Island Medical Marijuana Program (Edward O. Hawkins and Thomas C. Slater Medical Marijuana Act) and willing to evaluate Muscular Dystrophy cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Rhode Island honors out-of-state medical cards under its reciprocity rules — uncommon, and worth verifying before relying on it. Verify the patient minimum age with the state program before applying. The authoritative source for the current process is the Rhode Island Medical Marijuana Program (Edward O. Hawkins and Thomas C. Slater Medical Marijuana Act) site at https://dbr.ri.gov/divisions/medical-marijuana; the state updates fees, forms, and physician registration rules periodically.
What does the evidence say about cannabis for Muscular Dystrophy?
For Muscular Dystrophy, evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Muscular Dystrophy lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Muscular Dystrophy should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Muscular Dystrophy and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Muscular Dystrophy; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.
Sources
- Rhode Island General Laws Chapter 21-28.11: The Rhode Island Cannabis Actaccessed May 16, 2026
- Rhode Island General Laws Chapter 21-28.6: Edward O. Hawkins and Thomas C. Slater Medical Marijuana Actaccessed May 16, 2026
- Rhode Island Cannabis Control Commissionaccessed May 16, 2026
- Rhode Island Department of Business Regulation: Office of Cannabis Regulationaccessed May 16, 2026
- Wikipedia: Cannabis in Rhode Islandaccessed May 16, 2026
- NIH National Institute of Neurological Disorders and Stroke: Muscular Dystrophyaccessed May 18, 2026
- NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 18, 2026
“Substantial evidence that oral cannabinoids are effective antiemetics in the treatment of chemotherapy-induced nausea.”
- Muscular Dystrophy Association: About Neuromuscular Diseasesaccessed May 18, 2026
- MedlinePlus: Muscular dystrophyaccessed May 18, 2026
- FDA: Epidiolex (cannabidiol) prescribing informationaccessed May 18, 2026